These studies aim to evaluate

Canine stem cell Research Clinical trials

The phase-1 clinical trial of the anti-CD47 antibody is designed to test its safety. The trial will accrue one patient per month at very low doses, and the first groups of participants have been identified from among current Stanford Cancer patients. Currently we are not recruiting new patients to this trial.

If enrollments do open up in the future, that information will be posted on this page. When and if enrollments open up, potential inclusion in this phase-1 trial will be based solely on physician referrals. If there are openings for new participants, and if you meet certain requirements, information posted on this page will describe how your physician can submit a request to the clinical trials team to consider your participation.

Given the limited nature of this safety trial, we urge that patients not delay or forgo recommended treatments in hopes of participating in this research effort.

CD47 is a kind of protein that is found on the surface of many cells in the body. It tells circulating immune cells called macrophages not to eat these cells. The body uses the CD47 protein to protect cells that should be protected and to help dispose of cells that are aged or diseased. For instance, red blood cells start off with a lot of CD47 on their cell surface when young but slowly lose CD47 as they age. At some point, the amount of CD47 on the surface of an aging red blood cells is not enough to stave off the macrophages, and those older cells are devoured and destroyed, making way for new red blood cells. In this way, the supply of fresh blood cells is constantly replenished.

Unfortunately, some cells that should be destroyed are not. Researchers at Stanford have discovered that nearly every kind of cancer cell has a large amount of CD47 on the cell surface. This protein signal protects the cancer against attack by the body's immune system. Stanford investigators have discovered if that they block the CD47 "don't-eat-me" signal through the use of anti-CD47 antibodies, macrophages will consume and destroy cancer cells. Deadly human cancers have been diminished or eliminated in animal models through the use of anti-CD47 antibody.

You might also like
Pediatric stem cell transplants: Dr. Steven Margossian
Pediatric stem cell transplants: Dr. Steven Margossian ...
Stem Cell Therapies: Are We There Yet? - Larry Goldstein UCSD
Stem Cell Therapies: Are We There Yet? - Larry Goldstein UCSD
Related Posts